MARKET

DFTX

DFTX

Definium Therapeutics
NASDAQ
44.95
+0.16
+0.36%
After Hours: 44.80 -0.15 -0.34% 19:58 06/26 EDT
OPEN
44.70
PREV CLOSE
44.79
HIGH
45.75
LOW
42.84
VOLUME
12.21M
TURNOVER
--
52 WEEK HIGH
47.01
52 WEEK LOW
6.35
MARKET CAP
4.90B
P/E (TTM)
-18.0370
1D
5D
1M
3M
1Y
5Y
1D
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 1d ago
Definium Therapeutics (DFTX) Is Up 83.6% After DT120 Depression Trial Win And $700 Million Raise
Simply Wall St · 1d ago
Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired
NASDAQ · 2d ago
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Barchart · 2d ago
Psychedelic: Definium soars on study results for LSD-based depression treatment
TipRanks · 3d ago
Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday
Benzinga · 3d ago
Definium Therapeutics Announces Major Public Equity Offering
TipRanks · 3d ago
Definium Therapeutics Is Maintained at Buy by Jones Trading
Dow Jones · 3d ago
More
About DFTX
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Webull offers Definium Therapeutics Inc stock information, including NASDAQ: DFTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DFTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DFTX stock methods without spending real money on the virtual paper trading platform.